The abstract is read at the publisher; the summary is JClub's.
ALS-997, a BetA-derived compound, preferentially reduces uveal melanoma cell viability by disrupting autophagic flux and lysosomal function, linked to NPC1 engagement.
- Why it matters: Metastatic uveal melanoma often resists chemotherapy and current immunotherapies, and UM cells depend on lysosome-dependent stress responses such as autophagy.
- What they did: Using NCI-60 screening plus WST-1 viability assays, the study tested BetA derivatives and characterized ALS-997 effects with mTOR/autophagy western blots, LysoTracker Green and filipin III/LAMP2 staining, apoptosis markers, and NPC1 binding via cellular thermal shift and docking.
- The result: ALS-997 disrupted autophagic flux, caused lysosomal cholesterol accumulation, and increased PARP and caspase-3 cleavage while altering NPC1 thermal stability; NPC1 expression was higher in UM cells than in normal melanocytes, supporting NPC1 as a therapeutic target.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.